Psychiatry Department, Uşak University Medical Faculty, Uşak, Turkey.
J Nerv Ment Dis. 2022 Apr 1;210(4):257-263. doi: 10.1097/NMD.0000000000001500.
We aimed to explore the prevalence and determinants of severe COVID-19 disease and mortality in patients with schizophrenia in this study. We conducted a retrospective observational study of 1620 patients with schizophrenia. Of the 1620 patients, 52 (3.2%) tested positive for SARS-CoV-19. Among SARS-CoV-2-positive patients, 40 patients were hospitalized, and 17 patients required intensive care unit admission due to COVID-19 (76.9% and 32.7%, respectively). Severe COVID-19 disease was noted in 17 patients (32.7%) requiring intubation. In the logistic regression analysis, antipsychotic dose, and comorbidity score were independently associated with a greater risk of severe COVID-19 disease in patients with schizophrenia. Our study suggests that factors such as age, sex, comorbidities, and a daily antipsychotic dose may have effects on the poor outcome of SARS-CoV-2 disease in schizophrenia patients. In addition, the current findings propose that mortality may be associated with an older age, comorbidity score, and a longer duration of psychiatric disease among the SARS-CoV-2-positive patients with schizophrenia. However, the findings of our study should be verified in prospective and larger sample studies.
本研究旨在探讨精神分裂症患者中严重 COVID-19 疾病和死亡率的流行情况和决定因素。我们对 1620 例精神分裂症患者进行了回顾性观察性研究。在 1620 例患者中，有 52 例（3.2%）SARS-CoV-19 检测呈阳性。在 SARS-CoV-2 阳性患者中，有 40 例住院，17 例因 COVID-19 需要重症监护病房入院（分别为 76.9%和 32.7%）。严重 COVID-19 疾病在 17 例（32.7%）需要插管的患者中可见。在逻辑回归分析中，抗精神病药剂量和合并症评分与精神分裂症患者发生严重 COVID-19 疾病的风险增加独立相关。我们的研究表明，年龄、性别、合并症和每日抗精神病药剂量等因素可能对精神分裂症患者 SARS-CoV-2 疾病的不良结局产生影响。此外，目前的研究结果表明，死亡率可能与 SARS-CoV-2 阳性精神分裂症患者的年龄较大、合并症评分较高和精神疾病持续时间较长有关。然而，我们的研究结果需要在前瞻性和更大样本的研究中进行验证。
